Literature DB >> 33490271

COL1A1 Is a Potential Prognostic Biomarker and Correlated with Immune Infiltration in Mesothelioma.

Cangang Zhang1, Shanshan Liu2, Xin Wang1, Haiyan Liu1, Xiaobo Zhou1, Haibo Liu3.   

Abstract

OBJECTIVE: Mesothelioma (MESO) is a rare tumor derived from mesothelium cells. The aim of this study was to explore key candidate genes and potential molecular mechanisms for mesothelioma through bioinformatics analysis.
METHODS: The MESO expression profiles came from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. The differences in the infiltration levels of immune cells between MESO and normal tissues were assessed using CIBERSORT. Differentially expressed genes (DEGs) were identified by comprehensive analysis of multiple datasets. A protein-protein interaction (PPI) network was constructed, and a hub gene COL1A1 was selected for MESO. The expression and mutation of COL1A1 in MESO were analyzed in the cBioPortal database. The correlation between COL1A1 expression and immune cell infiltration was evaluated using the TIMER database. Gene Set Enrichment Analysis (GSEA) of COL1A1 was then performed. Finally, Kaplan-Meier survival analysis was presented to predict the survival times between high and low COL1A1 expression groups for MESO patients.
RESULTS: There were distinct differences in the infiltration levels of immune cells between MESO and normal tissues. A total of 118 DEGs were identified by comprehensively analyzing three expression profile datasets. COL1A1, a hub gene, was identified to be highly expressed in MESO compared to normal tissues. COL1A1 genetic mutation occurred in 9% of MESO samples, and amplification was the most common type of mutation. COL1A1 expression was significantly correlated to the infiltration levels of CD4+ T cells, macrophages, and neutrophils. GSEA results indicated that COL1A1 could be involved in key biological processes and pathways like extracellular matrix and PI3K-Akt pathway. Patients with high COL1A1 expression usually experienced shorten overall survival time than those with its low expression.
CONCLUSION: Our findings revealed that COL1A1 could become a potential prognostic biomarker for MESO, which was significantly related to immune cell infiltration.
Copyright © 2021 Cangang Zhang et al.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33490271      PMCID: PMC7803428          DOI: 10.1155/2021/5320941

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


  44 in total

Review 1.  Malignant mesothelioma as an oxidative stress-induced cancer: An update.

Authors:  Shan Hwu Chew; Shinya Toyokuni
Journal:  Free Radic Biol Med       Date:  2015-05-11       Impact factor: 7.376

2.  Versican modulates tumor-associated macrophage properties to stimulate mesothelioma growth.

Authors:  Apostolos G Pappas; Sophia Magkouta; Ioannis S Pateras; Ioannis Skianis; Charalampos Moschos; Maria Eleni Vazakidou; Katherina Psarra; Vassilis G Gorgoulis; Ioannis Kalomenidis
Journal:  Oncoimmunology       Date:  2018-11-02       Impact factor: 8.110

3.  Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.

Authors:  Floris Dammeijer; Lysanne A Lievense; Margaretha E Kaijen-Lambers; Menno van Nimwegen; Koen Bezemer; Joost P Hegmans; Thorbald van Hall; Rudi W Hendriks; Joachim G Aerts
Journal:  Cancer Immunol Res       Date:  2017-05-23       Impact factor: 11.151

4.  Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.

Authors:  Robert Ryan Meyerhoff; Chi-Fu Jeffrey Yang; Paul J Speicher; Brian C Gulack; Matthew G Hartwig; Thomas A D'Amico; David H Harpole; Mark F Berry
Journal:  J Surg Res       Date:  2015-01-29       Impact factor: 2.192

5.  Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human.

Authors:  Lisa Andzinski; Nadine Kasnitz; Stephanie Stahnke; Ching-Fang Wu; Marcus Gereke; Maren von Köckritz-Blickwede; Bastian Schilling; Sven Brandau; Siegfried Weiss; Jadwiga Jablonska
Journal:  Int J Cancer       Date:  2015-12-17       Impact factor: 7.396

6.  Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent.

Authors:  G Carteni; C Manegold; G Martin Garcia; S Siena; C C Zielinski; D Amadori; Y Liu; J Blatter; C Visseren-Grul; R Stahel
Journal:  Lung Cancer       Date:  2008-11-29       Impact factor: 5.705

7.  Prognostic value of transcriptomic determination of tumour-infiltrating lymphocytes in localised breast cancer.

Authors:  Caroline Truntzer; Nicolas Isambert; Laurent Arnould; Sylvain Ladoire; Francois Ghiringhelli
Journal:  Eur J Cancer       Date:  2019-09-06       Impact factor: 9.162

8.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

Authors:  Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz
Journal:  Cancer Discov       Date:  2012-05       Impact factor: 39.397

9.  LinkedOmics: analyzing multi-omics data within and across 32 cancer types.

Authors:  Suhas V Vasaikar; Peter Straub; Jing Wang; Bing Zhang
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

10.  Identification of COL1A1 as an invasion‑related gene in malignant astrocytoma.

Authors:  Shen Sun; Yue Wang; Yue Wu; Yue Gao; Qi Li; Ayanlaja Abiola Abdulrahman; Xin-Feng Liu; Guang-Quan Ji; Jin Gao; Li Li; Fa-Ping Wan; Yun-Qing Li; Dian-Shuai Gao
Journal:  Int J Oncol       Date:  2018-09-21       Impact factor: 5.650

View more
  9 in total

1.  ZIC5 promotes human hepatocellular carcinoma cell proliferation through upregulating COL1A1.

Authors:  Wenping Song; Weijiang Yu; Ding Li; Cheng Cheng; Xuan Wu; Jinhua Chen; Wenzhou Zhang
Journal:  J Gastrointest Oncol       Date:  2022-06

2.  A combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma.

Authors:  Thinh T Nguyen; Hyun-Sung Lee; Bryan M Burt; Christopher I Amos; Chao Cheng
Journal:  Br J Cancer       Date:  2022-08-23       Impact factor: 9.075

3.  LncRNA LINC00511 promotes COL1A1-mediated proliferation and metastasis by sponging miR-126-5p/miR-218-5p in lung adenocarcinoma.

Authors:  Yudong Wang; Xingke Mei; Weikang Song; Chen Wang; Xueshan Qiu
Journal:  BMC Pulm Med       Date:  2022-07-16       Impact factor: 3.320

4.  Plasma Proteins as Occupational Hazard Risk Monitors for Populations Working in Harsh Environments: A Mendelian Randomization Study.

Authors:  Ang Li; Wenjing Liao; Junyang Xie; Lijuan Song; Xiaowen Zhang
Journal:  Front Public Health       Date:  2022-05-06

Review 5.  Fibrosis in Mesothelioma: Potential Role of Lysyl Oxidases.

Authors:  Lara Perryman; Steven G Gray
Journal:  Cancers (Basel)       Date:  2022-02-15       Impact factor: 6.639

6.  Considering Computational Mathematics IGHG3 as Malignant Melanoma Is Associated with Immune Infiltration of Malignant Melanoma.

Authors:  Mengqing Si; Xianwei Cao
Journal:  Biomed Res Int       Date:  2022-04-18       Impact factor: 3.246

7.  From Bowen disease to cutaneous squamous cell carcinoma: eight markers were verified from transcriptomic and proteomic analyses.

Authors:  Tang Biao; He Cai-Feng; Lu Xiao-Hong; Chang Xiao-Li; Liu Wen-Bei; Wang Jun; Ci Chao; Yuan Tao
Journal:  J Transl Med       Date:  2022-09-09       Impact factor: 8.440

8.  Increased Expression of NXPH4 Correlates with Immune Cell Infiltration and Unfavorable Prognosis in Hepatocellular Carcinoma.

Authors:  Qin Tang; Yue-Ming Chen; Mei-Mei Shen; Wen Dai; Hang Liang; Jun-Nan Liu; Jian Gao
Journal:  J Oncol       Date:  2022-10-06       Impact factor: 4.501

9.  Gene Expression Analysis of Biphasic Pleural Mesothelioma: New Potential Diagnostic and Prognostic Markers.

Authors:  Rossella Bruno; Anello Marcello Poma; Greta Alì; Claudia Distefano; Agnese Proietti; Antonio Chella; Marco Lucchi; Franca Melfi; Renato Franco; Gabriella Fontanini
Journal:  Diagnostics (Basel)       Date:  2022-03-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.